Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Zemdri for cUTI, but issues CRL for bloodstream infections

June 27, 2018

Phase II trial evaluates antimalarial activity of single-dose DSM-265

June 27, 2018

Safety and efficacy of anti-PD-1 antibody SHR-1210 plus apatinib in refractory HCC, GC and EGJC

June 27, 2018

Enteris reports results from final arm of phase IIa trial of Ovarest

June 27, 2018

Increasing the sensitivity of mu-opioid receptors

June 27, 2018

Stemline Therapeutics completes rolling BLA submission to the FDA for Elzonris

June 27, 2018

Phase II results for CLT-008 in patients receiving AML induction therapy

June 27, 2018

First-in-human data reported for AMV-564 in patients with relapsed/refractory AML

June 27, 2018

Safety and immunogenicity of ZMapp antibody cocktail for Ebola virus tested in healthy adults

June 27, 2018

Navitor Pharmaceuticals initiates phase I trial of NV-5138 for treatment-resistant depression

June 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...